Think about the last time you dealt with the healthcare system. The forms you filled out for the fourth time. The hours you took off from work in order to spend 12 minutes with your doctor. The feeling that you were a case number in a system that doesn’t really know you.
That frustration can push you to look for answers elsewhere. How many of us have asked an AI chatbot a medical question, only to be reminded that it’s not a doctor and can’t provide medical advice? Or maybe it cited a study that doesn’t exist, misstated medicine dosages, or gave you false reassurance for a symptom that actually needed urgent attention.
Now imagine the opposite: you open an app and it already knows you. No form, just a conversation with a team that remembers your history and your goals. You can be confident the advice is real and current, vetted by actual clinicians, not hallucinated, and never out of date. And best of all, when you need a provider, there's a provider. The distance between the existing system and what we know is possible today requires a complete reinvention.
Today, we announced that Hims & Hers is building that – and we’re already making progress. We’re making a multi-year commitment to invest in AI. We’re creating the first doctor-led, AI-native care experience, rebuilding consumer health from the ground up. It’s the difference between adding an AI feature and reimagining the entire customer experience with AI as both the strategy and the foundation. And it’s what will make it possible to access the caliber of care that has only ever been within reach of the wealthy. Care that is personalized to your biology, unified with technology that can catch what an annual physical misses, designed to get you the right treatment the first time, and is delivered seamlessly.
Our CTO Mo and his team have spent the last year developing the foundation behind it all and we’re already seeing the impact. Last week, we launched a completely reimagined care experience for Hers weight-loss members and a few months ago we launched Labs AI. Early signs show customer engagement is up, AI is taking on more non-clinical tasks, and most importantly, providers on our platform are spending more time on the thing they’re best at: delivering care.
These results are so powerful that we’ve decided to accelerate our investment in bringing this experience to life for all of our customers. We announced in our Q2’26 earnings today that we’re increasing our AI investment by bringing new AI talent to the team, continuing to invest in our existing talent, and opening an AI R&D lab in Menlo Park, where our technical team can work together in person in the heart of Silicon Valley. We expect this investment to pay for itself within 12 to 18 months, and more importantly, we expect it will allow us to make our offerings more affordable for customers and to expand internationally more quickly.
Internally, we call this transformation Project Galen, after Galen of Pergamon, a second-century Greek physician, surgeon, and philosopher, whose theories are grounded in continuous, individualized observation rather than one-size-fits-all convention. That’s at the heart of what we believe in at Hims & Hers.
Galen is not about replacing doctors. Clinicians on our platforms stay in charge of all clinical activities and in the loop, making them more effective, not less needed. AI takes the routine work off of their plates so they can spend their time on the judgment and nuance each patient needs. Quality leads everything. Lower costs and broader access are what happen when care improves, not trade-offs against quality.
We believe this is something only we can do well, and the reason isn't just our technology. It's trust, and we’ve been building trust for nearly a decade. Over the course of nine years, millions of people have trusted us to help them feel comfortable seeking care for conditions that should be normalized. Those nine years include nine years of data that has enabled a continually deepening understanding of what works, for whom, and why. We believe we're the only company operating a true closed loop at this scale, from a customer's first question through treatment, follow-up, and the ultimate outcome. The system learns from all of it. The goal was never to just give you a second opinion – we believe we can bring you the value of a thousand opinions into your care.
The future of health won't be built by the companies with the best algorithms. It will be built by the ones people trust with their health who continue to earn that trust again, every single day. We've spent nearly a decade earning it. Now we're going to prove what’s possible when trust meets technology: healthcare that is personal, present, and built entirely around you.
This is the beginning. We can't wait to show you the rest.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "anticipates," "expects," "intends," "plans," "decides," "may," "will," "likely," "potential," "future," "over time," "coming," "hope," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, the rollout, availability, functionality, adoption and performance of our doctor-led, AI-native care experience and related platform features, including Project Galen; our increased investment in AI talent and infrastructure, including the planned AI research and development lab in Menlo Park; our expectations regarding the timing and financial impact of these investments, including the anticipated payback period, affordability improvements and international expansion; and our ability to enhance personalization, engagement, clinical support and customer outcomes through these offerings. These statements are based on management's current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and success of the rollout, availability and adoption of our doctor-led, AI-native care experience and related platform features, including Project Galen; our ability to successfully develop, deploy and maintain AI-powered technologies and integrate them into our platform and clinical workflows at scale; our ability to attract and retain AI talent and to successfully establish and operate the planned AI R&D lab in Menlo Park; our ability to realize the anticipated payback period, cost savings, affordability improvements and international expansion resulting from our increased AI investment within the expected timeframe, or at all; the accuracy, reliability and performance of AI-generated outputs and their acceptance by customers and providers; changes in the application, interpretation and enforcement of healthcare, consumer protection, privacy or artificial intelligence laws and regulations applicable to our business; and our ability to realize the anticipated benefits of these new products and features, and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of August 10, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
